Ms. Konski was recognized in the Legal 500 US 2009 Edition and in the Legal 500 US: Volume II: Intellectual Property, Media, Technology, and Telecom 2007 Guide as a top attorney for patent prosecution.

Ms. Konski works with life science clients, creating and optimizing value in intellectual property portfolios encompassing technologies that include personalized medicine, regenerative and stem cell biology, antibodies, immunology, gene therapy, nanotechnology, diagnostics, small molecules and drug delivery. She represents public and private companies and universities.

Ms. Konski practice includes:

• Identifying diverse commercial applications for early stage technologies
• Developing, prosecuting and managing global intellectual property portfolios
• Advising clients on preparing for due diligence investigations and conducting due diligence of target intellectual property
• Providing inventorship; patent invalidity, freedom to operate and non-infringement opinions
• Advising clients on domestic and foreign IP acquisitions
• Assisting clients resolve intellectual property disputes in non-litigious forums

Ms. Konski earned her J.D. degree from Fordham University School of Law where she was a member of the Urban Law Journal. She earned her Bachelor of Science degree from the University of Delaware where she was elected to Omicron Nu Honor Society. Before entering the legal profession, Ms. Konski was employed by Penn State Medical College in a molecular virology laboratory and later by Memorial Sloan-Kettering Cancer Center in a tumor immunology laboratory.

She is a member of the State Bar of California, the State Bar of New York, the Biotechnology Section of the American Bar Association and the American Intellectual Property Lawyers Association. She is registered to practice before the U.S. Patent and Trademark Office.

Ms. Konski is an active member of BayBio, Northern California's life science trade organization, where she serves as co-chair for the program committee. She is a frequent speaker and author on issues pertaining to global IP protection in the life sciences.

Selected Publications:

• Konski and Spielthenner, "Stem Cell Patents, A Landscape Analysis," Nature Biotechnology (Vol. 27(8), pages 722-726, 2009)
• Konski, Brinckenhoff, Nie, "Genes Under the Microscope – Novel or Not?" Intellectual Property Today (July, 2009)
• Konski, "IP Strategies to Combat Distribution of Counterfeit Drugs," BioProcess International (Vol. 6(3), pages 14-18, 2008)
• Konski and Dombach, "Strategies For Meeting the Challenge of Patenting Nanobio Inventions," Global Intellectual Property Asset Management Report (August 2007)
• Konski, "The IP Due Diligence – A User's Guide," Burrill Stem Cell Report (pages 68-71, March 2007)
• Medd and Konski, "Workplace Programs To Protect Trade Secrets," Nature Biotechnology (Vol. 21, pages 201-203, 2003)
• Konski, "The Utility Rejection in Biotechnology and Pharmaceutical Prosecution Practice," Journal of the Patent and Trademark Office Society (Vol. 76(11), page 821, 1994)

Selected Speeches and Presentations:

• "Fast Track to Action – A Look at the Patent Prosecution Highway," Palo Alto, California (May 1, 2009)
• "Antibody Patents: Getting the Scope You Deserve," San Diego, California (January 16, 2009)
• "Four Weeks to Go – Are You Current with Recent USPTO Rule Changes? A Closer Look at the New Written Description and Proposed Appeal Rules," Palo Alto, California (November 19, 2008)
• "Introduction to Adult and Embryonic Stem Cells," ABA Teleconference and Panel Discussion (November 18, 2008)
• "Stem Cell Patents: An Analysis," The Stem Cell Partnering Series conference, Fostering Business Collaborations & Careers in Stem Cell Science, San Diego, California (February 28, 2008)
• "Finding Value in the Most Overlooked Elements of the Due Diligence Process," Dive Deeper into Due Diligence: Enhanced Value for Life Sciences Companies, San Mateo, California (December 4, 2007)
• "A Paradigm Shift: Planning for and Coping with the Recent USPTO Rule Changes," San Mateo, California (September 19, 2007)
• "Strategic Alliance of Patent Portfolios with Nanotech Company Business Objectives," The 2nd International Congress of Nanobiotechnology & Nanomedicine (NanoBio2007), San Mateo, California (June 18-21, 2007)
• "Current Issues in Patenting Gene Sequences," ACI 8th Advanced Forum on Biotech Patents, Analysis, Insights and Strategies for New Challenges in Biotech Patent Practice, Menlo Park, California (April 18-19, 2007)
• "CIRM's IP Policy Moves Forward," The Stem Cell Meeting, Burrill & Co., San Francisco, California (March 12-13, 2007)
• "Creating a Practical and Useful Due Diligence Checklist," ACI 3rd National Conference on Life Sciences IP Due Diligence, Menlo Park, California (January 22, 2007)
• "Extra-Territorial Enforcement of US Patents," ACI 6th Advanced Forum on Biotech Patents, San Francisco, California (February 16-17, 2006)
• "The Changing Landscape of Chemical Patents and Related Intellectual Property," Panelist, Annual Meeting of American Chemical Society, Anaheim, California (March 28, 2004)

Commentary:

• Quoted in "Knives Come Out on Stem Cell Bill," Cheryl Miller, The Recorder (April 2, 2007)
• Quoted in "Stem Cell Agency Faces Thorny Questions Of Law," Eric Young, San Francisco Business Times (December 2, 2005)